Published in J Cell Physiol on August 01, 2009
Safety Study of CALAA-01 to Treat Solid Tumor Cancers | NCT00689065
Genomic screening with RNAi: results and challenges. Annu Rev Biochem (2010) 3.08
In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev (2014) 1.28
MicroRNAs as biomarkers in colorectal cancer. Am J Pathol (2010) 1.25
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets (2010) 1.11
Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun (2009) 1.04
Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int (2013) 0.93
MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI J (2015) 0.89
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis. BMC Cancer (2010) 0.88
Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One (2012) 0.87
Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes. Bioimpacts (2012) 0.87
Kinetics and Mechanisms of Oxidative Cleavage of HIV RRE RNA by Rev-Coupled Transition Metal Chelates. Chem Sci (2013) 0.84
Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC. Cancer Gene Ther (2012) 0.80
The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer (2010) 0.79
The pursuit of oncotargets through understanding defective cell regulation. Oncotarget (2010) 0.78
A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma. World J Urol (2010) 0.77
Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS). BMC Cancer (2015) 0.77
Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2-Δe8 isoform. Oncotarget (2016) 0.76
Anti-RhoC siRNAs inhibit the proliferation and invasiveness of breast cancer cells via modulating the KAI1, MMP9, and CXCR4 expression. Onco Targets Ther (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
RNA interference in adult mice. Nature (2002) 5.33
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov (2004) 4.73
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
The RNAi revolution. Nature (2004) 3.96
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res (2003) 3.39
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet (2002) 3.08
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 2.68
Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res (2005) 2.59
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
Lipid-based nanoparticles for nucleic acid delivery. Pharm Res (2007) 2.25
Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res (2003) 2.18
Chemically modified siRNA: tools and applications. Drug Discov Today (2008) 2.13
Progress and prospects: naked DNA gene transfer and therapy. Gene Ther (2003) 2.00
EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene (2004) 1.95
Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry (2004) 1.91
Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene (2004) 1.91
Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther (2006) 1.86
Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther (2003) 1.76
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene (2004) 1.70
Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res (2004) 1.67
New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med (1999) 1.62
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res (2003) 1.55
Therapeutic potential of RNA interference against cancer. Cancer Sci (2006) 1.49
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun (2003) 1.47
Delivery of RNA interference. Cell Cycle (2006) 1.43
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res (2004) 1.42
shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev (2007) 1.42
A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res (2005) 1.42
Gene silencing by adenovirus-delivered siRNA. FEBS Lett (2003) 1.37
Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol (2006) 1.37
RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene (2004) 1.35
Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol (2004) 1.35
Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res (2004) 1.33
Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res (2008) 1.31
Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med (2005) 1.30
Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med (2006) 1.29
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst (2004) 1.29
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest (2005) 1.23
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer (2007) 1.23
RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis (2006) 1.22
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res (2007) 1.21
Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res (2004) 1.19
Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol (2005) 1.15
Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg (2004) 1.12
Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets (2008) 1.11
Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther (2001) 1.08
Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm (2009) 1.06
Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev (2003) 1.04
Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des (2008) 1.04
Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02
siRNA, miRNA, and shRNA: in vivo applications. J Dent Res (2008) 1.02
Advances in the development of siRNA-based therapeutics for cancer. IDrugs (2008) 1.01
The fate of mRNA and rRNA in Escherichia coli. Brookhaven Symp Biol (1975) 1.01
Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther (2005) 0.97
Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J Pharm Sci (2009) 0.96
Non-viral gene therapy. Curr Opin Biotechnol (1994) 0.95
Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther (2005) 0.94
A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J Control Release (2008) 0.92
RNA interference as a gene-specific approach for molecular medicine. Curr Med Chem (2005) 0.92
Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm (2009) 0.92
Vectors for RNA interference. Curr Opin Mol Ther (2004) 0.91
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs (2008) 0.90
Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther (2005) 0.90
Utility of Epstein-Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs. Gene Ther (2007) 0.88
Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol (2009) 0.87
Physicochemical characterization of siRNA-peptide complexes. Biotechnol Prog (2009) 0.81
Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J Nanosci Nanotechnol (2008) 0.80
Knockdown of human p53 gene expression in 293-T cells by retroviral vector-mediated short hairpin RNA. Acta Biochim Biophys Sin (Shanghai) (2005) 0.80
[SiRNA technology, the gene therapy of the future?]. Orv Hetil (2008) 0.79
Biosafety in handling gene transfer vectors. Curr Protoc Hum Genet (2006) 0.78
Polymeric core-shell nanoparticles for therapeutics. Clin Exp Pharmacol Physiol (2006) 0.78
In vivo transfer and expression of genes coding for short interfering RNAs. Curr Pharm Biotechnol (2004) 0.77
[Viral and nonviral gene therapy for treatment of retinal diseases]. Ophthalmologe (2005) 0.76
Nuclear gene targeting using negatively charged liposomes. Int J Pharm (2000) 0.76
Commercial potential of RNAi. Mol Biosyst (2006) 0.76
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem (2005) 2.38
Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene (2004) 1.91
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer (2010) 1.48
Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene (2003) 1.41
Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget (2012) 1.40
Proteases and glioma angiogenesis. Brain Pathol (2005) 1.39
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene (2003) 1.36
RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene (2004) 1.35
Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol (2004) 1.35
Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol (2007) 1.34
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res (2007) 1.29
MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One (2011) 1.27
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer (2007) 1.23
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res (2007) 1.21
Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther (2006) 1.20
Cathepsin B as a cancer target. Expert Opin Ther Targets (2013) 1.19
siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol (2006) 1.16
Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem (2007) 1.16
Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene (2002) 1.15
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res (2004) 1.14
Axonal remyelination by cord blood stem cells after spinal cord injury. J Neurotrauma (2007) 1.13
Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene (2002) 1.12
Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway. Neurobiol Dis (2008) 1.11
Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget (2011) 1.09
Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol (2008) 1.08
Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer (2005) 1.08
Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas. PLoS One (2010) 1.08
SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol (2006) 1.06
Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer (2010) 1.05
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One (2010) 1.05
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res (2007) 1.05
Mesenchymal stem cells from rat bone marrow downregulate caspase-3-mediated apoptotic pathway after spinal cord injury in rats. Neurochem Res (2007) 1.05
Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene (2004) 1.05
Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol (2010) 1.04
uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol (2008) 1.04
RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells. Mol Cancer Ther (2006) 1.03
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res (2003) 1.03
Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol (2010) 1.03
Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma. PLoS One (2010) 1.02
Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene (2003) 1.02
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/β-catenin signaling is enhanced in irradiated medulloblastoma cells. J Biol Chem (2012) 1.02
MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal (2011) 1.01
Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res (2011) 1.00
Inherited predisposition to glioma. Neuro Oncol (2009) 0.99
Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res (2008) 0.99
Umbilical cord blood stem cell mediated downregulation of fas improves functional recovery of rats after spinal cord injury. Neurochem Res (2007) 0.99
The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer (2009) 0.99
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem (2007) 0.99
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene (2002) 0.99
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation. PLoS One (2010) 0.98
Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res (2007) 0.98
Inhibition of matrix metalloproteinase-2 enhances radiosensitivity by abrogating radiation-induced FoxM1-mediated G2/M arrest in A549 lung cancer cells. Int J Cancer (2009) 0.98
Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice. PLoS One (2011) 0.97
Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs (2012) 0.97
Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury. Neurobiol Dis (2009) 0.96
Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One (2010) 0.96
Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther (2010) 0.96
Antiangiogenic therapy in brain tumors. Expert Rev Neurother (2008) 0.95
Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res (2008) 0.95
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol (2007) 0.94
Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One (2010) 0.94
Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS One (2012) 0.94
Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol (2005) 0.93
Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol (2009) 0.93
MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One (2010) 0.93
Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer. Biochem Biophys Res Commun (2013) 0.93
Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett (2011) 0.92
Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene (2002) 0.92
Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells. Int J Oncol (2010) 0.92
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol (2006) 0.92
N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp Cell Res (2011) 0.92
SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res (2011) 0.91
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell (2013) 0.90
Suppression of MMP-2 attenuates TNF-α induced NF-κB activation and leads to JNK mediated cell death in glioma. PLoS One (2011) 0.90
p53- and Bax-mediated apoptosis in injured rat spinal cord. Neurochem Res (2011) 0.90
Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY) (2010) 0.89
Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT. Neuro Oncol (2011) 0.89
Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor. Mol Cancer (2011) 0.89
MMP-2 suppression abrogates irradiation-induced microtubule formation in endothelial cells by inhibiting αvβ3-mediated SDF-1/CXCR4 signaling. Int J Oncol (2013) 0.89
RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells. Int J Oncol (2009) 0.89
Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Int J Oncol (2003) 0.88
Glioma stem cell invasion through regulation of the interconnected ERK, integrin α6 and N-cadherin signaling pathway. Cell Signal (2012) 0.88
Down-regulation of uPAR and cathepsin B retards cofilin dephosphorylation. Int J Oncol (2006) 0.88
Knockdown of cathepsin B and uPAR inhibits CD151 and α3β1 integrin-mediated cell adhesion and invasion in glioma. Mol Carcinog (2012) 0.87
SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT. PLoS One (2012) 0.86
Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. Neuro Oncol (2010) 0.86
Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity. Clin Cancer Res (2007) 0.86
uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells. Neuro Oncol (2012) 0.86
Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol (2009) 0.85
Doxorubicin-mediated apoptosis in glioma cells requires NFAT3. Cell Mol Life Sci (2009) 0.85
Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration. BMC Cancer (2013) 0.85
Downregulation of matrix metalloproteinase-2 (MMP-2) utilizing adenovirus-mediated transfer of small interfering RNA (siRNA) in a novel spinal metastatic melanoma model. Int J Oncol (2008) 0.85
siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma. Mol Cancer Res (2010) 0.85
Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma. Angiogenesis (2012) 0.85
uPAR/cathepsin B overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR/cathepsin B down regulated meningioma. PLoS One (2011) 0.84
Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells. Mol Cancer Res (2010) 0.84
Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1. PLoS One (2011) 0.84